»
Side Effects of Drugs Annual
 
 

Side Effects of Drugs Annual, 1st Edition

A worldwide yearly survey of new data in adverse drug reactions

 
Side Effects of Drugs Annual, 1st Edition,Jeffrey Aronson,ISBN9780444594990
 
 
 

Side Effects of Drugs Annual

J Aronson   

Elsevier

9780444594990

9780444595034

904

240 X 165

Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions.

Print Book + eBook

USD 446.40
USD 744.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 377.00

eBook
eBook Overview

VST (VitalSource Bookshelf) format

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

USD 367.00
Add to Cart
 
 

Key Features

  • Provides a critical yearly survey of new data and trends
  • Special reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors
  • Description

    The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.

    Readership

    Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries.

    Jeffrey Aronson

    Affiliations and Expertise

    Reader in Clinical Pharmacology

    View additional works by Jeffrey K Aronson

    Side Effects of Drugs Annual, 1st Edition

    Series Page

    Contributors

    Special reviews

    Cumulative indexes of special reviews, Annuals 11–33

    1. Index of drugs

    2. Index of adverse reactions

    Table of Essays, Annuals 1–33

    Mechanistic and clinical descriptions of adverse drug reactions

    1 EIDOS

    2 DoTS

    Definitive (between-the-eyes) adverse drug reactions

    How to use this book

    The scope of the Side Effects of Drugs Annuals

    Period covered

    Selection of material

    Classification of drugs

    Names of drugs and chemicals

    System of tagging references

    Indexes

    Abbreviations

    Side effects of drugs essay

    An agenda for research into adverse drug reactions

    Systematic reviews

    Teleoanalysis

    Conclusions

    1. Central nervous system stimulants and drugs that suppress appetite

    Amphetamines [SED-15, 180; SEDA-31, 1; SEDA-32, 1; SEDA-33, 1]

    Methylxanthines

    Drugs that suppress appetite [SEDA-30, 7; SEDA-31, 9; SEDA-32, 16; SEDA-33, 13]

    Drugs used in Alzheimer’s disease [SEDA-31, 10; SEDA-32, 19; SEDA-33, 15]

    References

    2. Antidepressant drugs

    General

    Selective serotonin re-uptake inhibitors (SSRIs) [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26]

    Serotonin and noradrenaline re-uptake inhibitors (SNRIs)

    Tricyclic antidepressants

    Other antidepressants

    References

    3. Lithium

    References

    4. Drugs of abuse

    Cannabinoids [SED-15, 614; SEDA-31, 33; SEDA-32, 55; SEDA-33, 55]

    Opioid analgesics

    References

    5. Hypnosedatives and anxiolytics

    Azaspirones [SEDA-32, 75; SEDA-33, 71]

    Benzodiazepines [SED-15, 429; SEDA-31, 57; SEDA-32, 75; SEDA-33, 71]

    Benzodiazepine-like drugs

    Benzodiazepine antagonists

    Other hypnosedatives

    References

    6. Antipsychotic drugs

    General [SED-15, 2438; SEDA-32, 83; SEDA-33, 89]

    Individual drugs

    References

    7. Antiepileptic drugs

    General

    References

    8. Opioid analgesics and narcotic antagonists

    General

    Opioid receptor agonists

    Partial opioid receptor agonists

    Opioid receptor antagonists

    References

    9. Anti-inflammatory and antipyretic analgesics and drugs used in gout

    Amidopyrine and related compounds

    Aniline derivatives [SED-15, 2679; SEDA-33, 244]

    Anthranilic acid derivatives

    Arylalkanoic acid derivatives [SED-15, 2555; SEDA-31, 186; SEDA-32, 229; SEDA-33, 245]

    COX-2-selective inhibitors [SEDA-31, 190; SEDA-32, 232; SEDA-33, 246]

    Indoleacetic acids [SEDA-33, 247]

    Oxicams [SED-15, 2555; SEDA-32, 233; SEDA-33, 247]

    Salicylates [SED-15, 15; SEDA-30, 128; SEDA-33, 248]

    Miscellaneous drugs

    Drugs used in the treatment of gout

    References

    10. General anesthetics and therapeutic gases

    Anesthetic vapors [SEDA-31, 217; SEDA-32, 243; SEDA-33, 257]

    Other vapors

    Intravenous agents: Non-barbiturate anesthetics

    Intravenous agents: Barbiturate anesthetics

    References

    11. Local anesthetics

    General

    Effects related to modes of use [SED-15, 2121; SEDA-31, 233; SEDA-32, 262; SEDA-33, 281]

    Caudal, epidural, and spinal anesthesia

    Tumescent anesthesia

    Individual compounds

    References

    12. Neuromuscular blocking agents and skeletal muscle relaxants

    Depolarizing neuromuscular blocking agents

    Non-depolarizing neuromuscular blocking agents [SED-15, 2489; SEDA-31, 248; SEDA-32, 274; SEDA-33, 301]

    Skeletal muscle relaxants

    References

    13. Drugs that affect autonomic functions or the extrapyramidal system

    Drugs that stimulate both alpha- and beta-adrenoceptors [SEDA-31, 259; SEDA-32, 281; SEDA-33, 313]

    Drugs that predominantly stimulate alpha1-adrenoceptors [SEDA-31, 264; SEDA-32, 283; SEDA-33, 318]

    Drugs that stimulate beta1-adrenoceptors [SEDA-31, 265; SEDA-32, 284; SEDA-33, 265]

    Drugs that stimulate beta2-adrenoceptors

    Drugs that stimulate dopamine receptors [SEDA-31, 2039; SEDA-33, 266]

    Other drugs that increase dopamine activity

    Drugs that affect the cholinergic system [SEDA-31, 272; SEDA-32, 290; SEDA-33, 324]

    References

    14. Dermatological drugs, topical agents, and cosmetics

    Cosmetics

    Dermal fillers

    Dyestuffs [SEDA-15, 1573; SEDA-31, 288; SEDA-32, 296]

    Hair straighteners [SEDA-32, 296]

    Fragrances

    Glucocorticoids, topical

    Phototherapy and photochemotherapy [SED-15, 2823; SEDA-32, 297]

    Sunscreens

    Vitamin A (retinoids) [SED-15, 3653; SEDA-32, 298; for vitamin A carotenoids seeChapter 34]

    Vitamin D analogues, topical [SED-15, 594; SEDA-31, 293; SEDA-32, 301; for oral vitamin D analogues seeChapter 34]

    References

    15. Antihistamines (H1 receptor antagonists)

    References

    16. Drugs that act on the respiratory tract

    Inhaled glucocorticoids [SEDA-31, 305; SEDA-32, 311; SEDA-33, 353]

    Nasal glucocorticoids

    Beta2-adrenoceptor agonists [SEDA-31, 308; SEDA-32, 314; SEDA-33, 357]

    Anticholinergic drugs [SEDA-31, 311; SEDA-32, 318; SEDA-33, 363]

    Leukotriene modifiers [SEDA-31, 312; SEDA-32, 319; SEDA-33, 366]

    Phosphodiesterase type IV inhibitors [SEDA-31, 313; SEDA-32, 321; SEDA-33, 367]

    References

    17. Positive inotropic drugs and drugs used in dysrhythmias

    Cardiac glycosides [SED-15, 648; SEDA-31, 321; SEDA-32, 333; SEDA-33, 377]

    Herbal glycosides

    Other positive inotropic drugs [SED-15, 2822; SEDA-31, 323; SEDA-32, 336; SEDA-33, 378]

    Antidysrhythmic drugs

    Adenosine receptor agonists [SEDA-31, 324; SEDA-32, 337; SEDA-33, 379]

    References

    18. Beta-adrenoceptor antagonists and antianginal drugs

    Beta-adrenoceptor antagonists [SED-15, 452; SEDA-31, 339; SEDA-32, 363; SEDA-33, 397]

    Potassium channel activators

    Nitrates, organic [SED-15, 2529; SEDA-32, 366; SEDA-33, 400]

    Calcium channel blockers [SED-15, 598; SEDA-31, 340; SEDA-32, 366; SEDA-33, 401]

    References

    19. Drugs acting on the cerebral and peripheral circulations

    Drugs used in the treatment of arterial disorders of the brain and limbs

    Drugs used in the treatment of venous disorders

    Drugs used in the treatment of migraine

    Other peripheral vasodilators

    References

    20. Antihypertensive drugs

    General

    Angiotensin-converting enzyme inhibitors [SED-15, 226; SEDA-31, 350; SEDA-32, 379; SEDA-33, 416]

    Angiotensin II receptor antagonists [SED-15, 223; SEDA-31, 358; SEDA-32, 387; SEDA-33, 418]

    Dual angiotensin II receptor antagonists/neprilysin antagonists

    Direct renin inhibitors [SEDA-31, 360; SEDA-32, 388; SEDA-33, 420]

    Endothelin receptor antagonists [SED-15, 1215; SEDA-31, 360; SEDA-32, 389; SEDA-33, 421]

    Drugs that act on the sympathetic nervous system [SEDA-31, 362; SEDA-32, 391; SEDA-33, 424]

    Postsynaptic α-adrenoceptor antagonists [SEDA-31, 363; SEDA-32, 391; SEDA-33, 425]

    Direct vasodilators

    References

    21. Diuretics

    Carbonic anhydrase inhibitors [SED-15, 643; SEDA-31, 371; SEDA-32, 403; SEDA-33, 437]

    Thiazide and thiazide-like diuretics [SED-15, 3375; SEDA-31, 372; SEDA-32, 405; SEDA-33, 438]

    Loop diuretics [SED-15, 567, 1454; SEDA-31, 375; SEDA-32, 408; SEDA-33, 440]

    Aldosterone receptor antagonists

    Spironolactone [SED-15, 3176; SEDA-31, 375; SEDA-32, 409; SEDA-33, 440]

    Osmotic diuretics

    References

    22. Metals

    References

    23. Metal antagonists

    Iron chelators

    Penicillamine and related drugs [SED-15, 2729; SEDA-31, 403; SEDA-32, 430; SEDA-33, 472]

    Other chelators

    Polystyrene sulfonates [SED-15, 2894; SEDA-32, 433; SEDA-33, 474]

    References

    24. Antiseptic drugs and disinfectants

    Aldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437; SEDA-33, 479]

    Bisbiguanides

    Cationic surfactants

    Halogens

    Iodophors [SED-15, 1896; SEDA-31, 411; SEDA-32, 440; SEDA-33, 485]

    Phenolic compounds [SED-15, 2800; SEDA-32, 441; SEDA-33, 485]

    References

    25. Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines

    Beta-lactam antibiotics [SED-15, 478; SEDA-31, 420; SEDA-32, 447; SEDA-33, 491]

    Carbapenems [SED-15, 638; SEDA-31, 420; SEDA-32, 448; SEDA-33, 491]

    Cephalosporins [SED-15, 688; SEDA-31, 422; SEDA-32, 448; SEDA-33, 493]

    Monobactams and monocarbams [SED-15, 2378; SEDA-31, 423; SEDA-32, 450; SEDA-33, 494]

    Penicillins [SED-15, 2756; SEDA-31, 424; SEDA-32, 450; SEDA-33, 495]

    Tetracyclines and glycylcyclines [SED-15, 3330; SEDA-31, 419; SEDA-32, 451; SEDA-33, 497]

    References

    26. Miscellaneous antibacterial drugs

    Aminoglycosides [SED-15, 118; SEDA-31, 427; SEDA-32, 461; SEDA-33, 509]

    Fluoroquinolones [SED-15, 1396; SEDA-31, 429; SEDA-32, 464; SEDA-33, 514]

    Glycopeptides [SEDA-31, 435; SEDA-32, 469; SEDA-33, 519]

    Ketolides [SED-15, 1976; SEDA-31, 436; SEDA-32, 471; SEDA-33, 521]

    Lincosamides [SED-15, 2063; SEDA-31, 437; SEDA-32, 472; SEDA-33, 522]

    Macrolides [SED-15, 2183; SEDA-31, 437; SEDA-32, 472; SEDA-33, 522]

    Nitrofurantoin [SED-15, 2542; SEDA-31, 439; SEDA-32, 476; SEDA-33, 525]

    Oxazolidinones [SED-15, 2645; SEDA-31, 439; SEDA-32, 474; SEDA-33, 525]

    Polymyxins [SED-15, 2891; SEDA-31, 441; SEDA-32, 476; SEDA-33, 527]

    Streptogramins [SED-15, 3182; SEDA-31, 442; SEDA-32, 528]

    Sulfonamides, trimethoprim, and co-trimoxazole [SED-15, 3216, 3510; SEDA-31, 442; SEDA-32, 477; SEDA-33, 528]

    Other antimicrobial drugs

    References

    27. Antifungal drugs

    Allylamines [SEDA-31, 457; SEDA-32, 491; SEDA-33, 541]

    Amphotericin [SED-15, 192; SEDA-31, 458; SEDA-32, 493; SEDA-33, 542]

    Antifungal azoles [SED-15, 301; SEDA-31, 459; SEDA-32, 497; SEDA-33, 545]

    Echinocandins [SED-15, 1197; SEDA-31, 464; SEDA-32, 507; SEDA-33, 556]

    Flucytosine [SED-15, 1388; SEDA-32, 497; SEDA-33, 000]

    References

    28. Antiprotozoal drugs

    Antimalarial drugs

    4-Aminoquinolines (chloroquine and congeners) [SEDA-31, 469; SEDA-32, 521; SEDA-33, 567]

    Primaquine and congeners [SED-15, 2919; SEDA-33, 569]

    Endoperoxides [SED-15, 342; SEDA-31, 473; SEDA-32, 525; SEDA-33, 571]

    Drugs used in the treatment of other protozoal infections

    Miscellaneous drugs

    References

    29. Antiviral drugs

    Drugs active against cytomegalovirus

    Drugs active against herpesviruses [SEDA-31, 478; SEDA-32, 530; SEDA-33, 577]

    Drugs active against hepatitis viruses

    Drugs active against human immunodeficiency virus: Combinations

    Drugs active against human immunodeficiency virus: Nucleoside analogue reverse transcriptase inhibitors (NRTI) [SED-15, 2586; SEDA-31, 482; SEDA-32, 534; SEDA-33, 585]

    Drugs active against human immunodeficiency virus: Nucleotide analogue reverse transcriptase inhibitors

    Drugs active against human immunodeficiency virus: Non-nucleoside reverse transcriptase inhibitors (NNRTI) [SED-15, 2553; SEDA-31, 486; SEDA-32, 537; SEDA-33, 590]

    Drugs active against human immunodeficiency virus: Protease inhibitors [SED-15, 2586; SEDA-31, 487; SEDA-32, 541; SEDA-33, 593]

    Drugs active against human immunodeficiency virus: Inhibitors of HIV fusion [SEDA-28, 337; SEDA-33; 598; SEDA-33, 598]

    Drugs active against human immunodeficiency virus: Integrase inhibitors [SEDA-33, 599]

    Drugs active against human immunodeficiency virus: Chemokine receptor CCR5 antagonists [SEDA-33, 600]

    Drugs active against influenza viruses: Neuraminidase inhibitors [SED-15, 2436; SEDA-31, 489; SEDA-32, 544; SEDA-33, 601]

    Drugs active against influenza viruses: Ion channel inhibitors [SED-15, 105, 3051; SEDA-31, 489; SEDA-32, 544; SEDA-33, 269, 602]

    References

    30. Drugs used in tuberculosis and leprosy

    Rifamycins [SED-15, 3040; SEDA-31, 498; SEDA-32, 563; SEDA-33, 637]

    References

    31. Antihelminthic drugs

    Benzimidazoles [SED-15, 424; SEDA-31, 508; SEDA-32, 572; SEDA-33, 647]

    References

    32. Vaccines

    General

    Bacterial vaccines

    Viral vaccines

    Other components of vaccines

    References

    33. Blood, blood components, plasma, and plasma products

    Albumin and derivatives [SED-15, 54; SEDA-31, 527; SEDA-32, 591; SEDA-33, 670]

    Blood transfusion [SED-15, 529; SEDA-31, 528; SEDA-32, 593; SEDA-33, 671]

    Blood substitutes [SEDA-31, 531; SEDA-32, 593; SEDA-33, 672]

    Plasma and plasma products [SED-15, 2847; SEDA-31, 532; SEDA-32, 594; SEDA-33, 674]

    Plasma substitutes [SEDA-31, 533; SEDA-32, 594; SEDA-33, 675]

    Globulins

    Coagulation proteins [SED-15, 845; SEDA-31, 537; SEDA-32, 596; SEDA-33, 679]

    Erythropoietin and derivatives [SED-15, 1243; SEDA-31, 538; SEDA-32, 597; SEDA-33, 681]

    Stem cells [SEDA-31, 539; SEDA-32, 599; SEDA-33, 682]

    References

    34. Vitamins, intravenous solutions, and drugs and formulations used in nutrition

    Vitamin A (carotenoids) [SED-15, 3642; SEDA-31, 548; SEDA-32, 607; SEDA-33, 691]

    Vitamins of the B group [SED-15, 2700; SEDA-31, 548; SEDA-32, 608; SEDA-33, 693]

    Vitamin C (ascorbic acid) [SED-15, 351; SEDA-31, 548; SEDA-32, 611; SEDA-33, 694]

    Vitamin D analogues [SED-15, 3669; SEDA-31, 549; SEDA-32, 612; SEDA-33, 695]

    Vitamin E (tocopherol) [SED-15, 3677; SEDA-31, 549; SEDA-32, 612; SEDA-33, 696]

    Vitamin K analogues [SED-15, 3681; SEDA-29, 355]

    Parenteral nutrition [SED-15, 2700; SEDA-31, 549; SEDA-32, 613; SEDA-33, 697]

    Enteral nutrition [SED-15, 1221; SEDA-30, 396; SEDA-33, 700]

    References

    35. Drugs that affect blood coagulation, fibrinolysis, and hemostasis

    Coumarin anticoagulants [SED-15, 983; SEDA-31, 553; SEDA-32, 617; SEDA-33, 707]

    Heparins [SED-15, 1590; SEDA-31, 556; SEDA-32, 626; SEDA-33, 713]

    Direct thrombin inhibitors [SED-15, 1142; SEDA-30, 409; SEDA-31, 559; SEDA-32, 632; SEDA-33, 717]

    Direct factor Xa inhibitors [SEDA-31, 561; SEDA-32, 635]

    Indirect factor Xa Inhibitors [SEDA-31, 563; SEDA-32, 636; SEDA-33, 636]

    Thrombolytic drugs

    Drugs that alter platelet function [SEDA-30, 413; SEDA-31, 564; SEDA-32, 637; SEDA-33, 637]

    Glycoprotein IIb–IIIa inhibitors [SED-15, 4; SEDA-31, 565; SEDA-32, 638; SEDA-33, 720]

    Thienopyridines [SED-15, 821; SEDA-31, 566; SEDA-32, 639; SEDA-33, 720]

    Hemostatic agents

    References

    36. Gastrointestinal drugs

    Antacids [SED-15, 243; SEDA-31, 573; SEDA-32, 665; SEDA-33, 741]

    Antiemetics and drugs that affect gastrointestinal motility [SEDA-31, 573; SEDA-32, 665; SEDA-33, 741]

    5HT3 receptor antagonists [SED-15, 1365; SEDA-31, 575; SEDA-32, 666; SEDA-33, 744]

    Neurokinin NK1 receptor antagonists [SEDA-32, 667; SEDA-33, 748]

    Histamine H2 receptor antagonists [SED-15, 1629; SEDA-31, 576; SEDA-32, 667; SEDA-33, 748]

    Proton pump inhibitors [SED-15, 2973; SEDA-31, 577; SEDA-32, 667; SEDA-33, 749]

    Other ulcer-healing agents

    Laxatives and oral bowel preparations [SED-15, 2008; SEDA-31, 581; SEDA-32, 668; SEDA-33, 753]

    Aminosalicylates [SED-15, 138; SEDA-31, 583; SEDA-32, 669; SEDA-33, 756]

    Antidiarrheal agents

    Other gastrointestinal agents

    References

    37. Drugs that act on the immune system: cytokines and monoclonal antibodies

    Colony-stimulating factors [SEDA-31, 589; SEDA-32, 675; SEDA-33, 769]

    Interferons [SED-15, 1841; SEDA-31, 591; SEDA-32, 676; SEDA-33, 773]

    Interleukins [SED-15, 1831; SEDA-31, 592; SEDA-32, 676; SEDA-33, 777]

    Tumor necrosis factor alfa (TNF-α) and its antagonists [SEDA-31, 592; SEDA-32, 677; SEDA-33, 779]

    Monoclonal antibodies [SED-15, 2380; SEDA-31, 602; SEDA-32, 686; SEDA-33, 783]

    References

    38. Drugs that act on the immune system

    Thiopurines [SED-15, 377; SEDA-31, 635; SEDA-32, 717; SEDA-33, 824]

    Immunoenhancing drugs

    References

    39. Corticotrophins, corticosteroids, and prostaglandins

    Systemic glucocorticoids [SED-15, 906; SEDA-31, 651; SEDA-32, 723; SEDA-33, 841]

    Prostaglandins and analogues [SED-15, 2955; SEDA-31, 651; SEDA-32, 729; SEDA-33, 846]

    References

    40. Sex hormones and related compounds, including hormonal contraceptives

    Estrogens [SED-15, 1253; SEDA-31, 657; SEDA-32, 736; SEDA-33, 852]

    Hormonal contraceptives [SED-15, 1642; SEDA-31, 663; SEDA-32, 741; SEDA-33, 858]

    Antiestrogens and selective estrogen receptor modulators (SERMs) [SEDA-31, 664; SEDA-32, 743; SEDA-33, 859]

    Progestogens [SED-15, 2930; SEDA-31, 669; SEDA-32, 747; SEDA-33, 865]

    Prostaglandins (See alsoChapters 39 and 47)

    Progesterone antagonists [SEDA-31, 671; SEDA-32, 749; SEDA-33, 866]

    Sex hormone antagonists

    Anabolic steroids, androgens, and related compounds [SED-15, 216; SEDA-31, 672; SEDA-32, 751; SEDA-33, 868]

    Antiandrogens [SEDA-31, 673; SEDA-32, 755; SEDA-33, 872]

    References

    41. Thyroid hormones, iodine, and antithyroid drugs

    Thyroid hormones [SED-15, 3409; SEDA-31, 687; SEDA-32, 763; SEDA-33, 881]

    Iodine and iodides [SED-15, 1896; SEDA-31, 688; SEDA-32, 764; SEDA-33, 883]

    Antithyroid drugs [SED-15, 3387; SEDA-31, 689; SEDA-32, 765; SEDA-33, 884]

    References

    42. Insulin, other hypoglycemic drugs, and glucagon

    Insulin [SED-15, 1761; SEDA-31, 689; SEDA-32, 769; SEDA-33, 889]

    Amylin analogues [SEDA-31, 692; SEDA-32, 773; SEDA-33, 893]

    Biguanides [SED-15, 506; SEDA-31, 692; SEDA-32, 773; SEDA-33, 893]

    Dipeptidyl peptidase 4 (DDP-4) inhibitors [SEDA-31, 693; SEDA-32, 774; SEDA-33, 894]

    Incretin mimetics [SEDA-31, 695; SEDA-32, 775; SEDA-33, 896]

    Meglitinides [SED-15, 2238; SEDA-31, 695; SEDA-32, 776; SEDA-33, 897]

    Sodium–glucose transporter type 2 (SGLT2) inhibitors [SEDA-33, 898]

    Sulfonylureas [SED-15, 3230; SEDA-31, 695; SEDA-32, 777; SEDA-33, 898]

    Thiazolidinediones (Glitazones) [SED-15, 3380; SEDA-31, 697; SEDA-32, 779; SEDA-33, 899]

    Peroxisome proliferator-activated dual receptor agonists [SEDA-32, 782; SEDA-33, 902]

    References

    43. Miscellaneous hormones

    Vasopressin receptor antagonists

    Vasopressin and analogues [SED-15, 3609; SEDA-31, 710; SEDA-32, 798; SEDA-33, 915]

    References

    44. Drugs that affect lipid metabolism

    Cholesteryl ester transfer proteins [SEDA-32, 817; SEDA-33, 929]

    Fibrates [SED-15, 1358; SEDA-32, 804; SEDA-33, 922]

    HMG-CoA REDUCTASE INHIBITORS [SED-15, 1632; SEDA-31, 715; SEDA-32, 807; SEDA-33, 924]

    Nicotinic acid derivatives [SED-15, 2512; SEDA-32, 815; SEDA-33, 928]

    References

    45. Cytostatic and cytotoxic drugs

    Pyrimidine analogues and fluoropyrimidines

    Pyrimidine analogues

    Fluoropyrimidines

    References

    46. Radiological contrast agents and radiopharmaceuticals

    MRI contrast media

    Ultrasound contrast agents [SED-15, 3543; SEDA-32, 855; SEDA-33, 971]

    Radiopharmaceuticals [SED-15, 3017; SEDA-33, 973]

    References

    47. Drugs used in ocular treatment

    Drugs used in the management of macular degeneration [SEDA-31, 739; SEDA-32, 865; SEDA-33, 977]

    Adrenoceptor agonists [SEDA-31, 740; SEDA-32, 869; SEDA-33, 982]

    Alpha-adrenoceptor agonists

    Antibacterial drugs

    Anticholinergic drugs

    Carbonic anhydrase inhibitors

    Glucocorticosteroids [SED-15, 906; SEDA-31, 741; SEDA-32, 871; SEDA-33, 983]

    Non-steroidal anti-inflammatory drugs

    Prostaglandin analogues (See also Chapter 39)[SEDA-32, 871; SEDA-33, 984]

    Procedures

    References

    48. Treatments used in complementary and alternative medicine

    Asian herbal medicines [SED-15, 1609; SEDA-32, 879]

    Oral formulations of traditional Chinese medicines

    Topical formulations of traditional Chinese medicines

    Injectable formulations of Chinese medicines

    Nutritional supplements

    Specific plants

    Acupuncture

    Infrared heat and massage therapy

    References

    49. Miscellaneous drugs, materials, medical devices, and techniques

    DyestuffS

    Sclerosants [SED-15, 3107; SEDA-33, 1021]

    References

    Index of drugs

    Index of drug-drug interactions

    Index of adverse effects and adverse reactions

     
     
    Free Shipping
    Shop with Confidence

    Free Shipping around the world
    ▪ Broad range of products
    ▪ 30 days return policy
    FAQ

    Contact Us